Onishchenko V V, Sokolova G B, Koriakin V A, Shapatava M N, Iurchenko L N
Probl Tuberk. 1990(7):43-5.
The outcomes of tisamid treatment of newly diagnosed patients with bacillary pulmonary tuberculosis were analysed. To estimate the efficacy of tisamid and its administration indications, chemotherapy of the patients was performed with the use of two therapeutic regimens. Isoniazid, rifampicin and streptomycin (or ethambutol) were given to 73 patients, while other 72 ones were treated with the same drugs plus tisamid. The patients in each group were subdivided into slow, rapid and homozygotic (the most rapid) acetylators. Tisamid, when prescribed to newly-discovered patients with destructive tuberculosis, accelerates recovery, by excluding the risk of a hepatotoxic action. Tisamid in a combined treatment with isoniazid, rifampicin and streptomycin is mostly recommended for patients with a rapid acetylation phenotype, i.e. the cases for whom a short-term chemotherapy is possible.
分析了替沙米德治疗新诊断的细菌性肺结核患者的疗效。为评估替沙米德的疗效及其给药指征,采用两种治疗方案对患者进行化疗。73例患者接受异烟肼、利福平及链霉素(或乙胺丁醇)治疗,另外72例患者在使用相同药物的基础上加用替沙米德。每组患者又分为慢乙酰化者、快乙酰化者和纯合子(最快)乙酰化者。当给新发现的有破坏性肺结核的患者使用替沙米德时,可排除肝毒性作用风险,从而加速康复。替沙米德与异烟肼、利福平及链霉素联合治疗时,最推荐用于快乙酰化表型的患者,即适合进行短期化疗的患者。